海正藥業(600267.SH):注射用紫杉醇(白蛋白結合型)獲批上市
格隆匯6月24日丨海正藥業(600267.SH)公吿,公司於近日收到國家藥品監督管理局核准簽發的注射用紫杉醇(白蛋白結合型)的《藥品註冊證書》。
注射用紫杉醇(白蛋白結合型)適用於治療聯合化療失敗的轉移性乳腺癌或輔助化療後6個月內復發的乳腺癌,除非有臨牀禁忌症,既往化療中應包括一種蒽環類抗癌藥。
經查詢IMS數據庫,注射用紫杉醇(白蛋白結合型)2020年國內市場銷售額約為3.1705億美元;2021年1-3月國內市場銷售額約為9873.28萬美元。
由於醫藥產品具有高科技、高風險、高附加值的特點,不僅藥品的前期研發以及產品從研製、臨牀試驗報批到投產的週期長、環節多,而且藥品獲得證書後生產和銷售也容易受到一些不確定性因素的影響。請投資者謹慎決策。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.